Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitacost faces dissident shareholder

This article was originally published in The Tan Sheet

Executive Summary

Boca Raton, Fla.-based Vitacost.com hires a financial advisor to help it identify "potential business combination partners and purchaser candidates." The May 20 announcement came five days before Vitacost's largest shareholder, Great Hill Equity Parnters, proposed four nominees to replace current board members. The shareholder explained the online dietary supplement retailer has experienced "significant erosion in stockholder value" since its 2009 initial public offering, according to a release. Great Hill attributes Vitacost's flat sales growth, high turnover and troubled manufacturing and logistics to "a board comprised of directors with little, if any, public company or Internet, eCommerce or direct marketing experience.

You may also be interested in...



Vitacost stockholder shakes up board

Great Hill Equity Partners, the largest holder of stock in Vitacost.com, will replace four company directors following a vote by Vitacost investors. An independent inspector of election confirmed the results July 21. Ira Kerker, CEO of Boca Raton, Fla.-based Vitacost, said, "The company's stockholders have spoken and we respect their decision." Great Hill offered its director nominees after communicating disppointment with the supplement retailer's flat sales growth and troubled manufacturing (1"The Tan Sheet" May 31, 2010, In Brief)

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy

Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.

Topics

UsernamePublicRestriction

Register

PS104168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel